Intellego Technologies (INT) Investor Update summary
Event summary combining transcript, slides, and related documents.
Investor Update summary
22 Sep, 2025Recent financial performance and outlook
Achieved strong Q2 results with significant revenue growth, improved margins, and a cash balance of approximately €9 million at quarter-end.
EBIT margin and operating cash flow have shown notable improvement, with Q2 EBIT margin reaching 71%, though future margins are expected to normalize as the organization expands.
Revenue for the group reached about €40 million by the end of Q2, with a three to five-year target of €200 million in revenue and €60 million EBIT.
Cash flow and liquidity are supported by a combination of cash in bank, credit-assured receivables, and unused credit, with EKN (Swedish Export Credit Agency) providing risk mitigation for larger export receivables.
The board is considering options for excess cash, including acquisitions, buybacks, or dividends.
Market position, growth strategy, and customer base
Operates in large, growing markets: UV disinfection, UV curing, and horticulture, with the disinfection market alone estimated at €1.6 billion annually.
Collaborations with major industry players like Henkel and Likang are key to growth, though scaling these partnerships takes time due to long lead times and gradual order increases.
Customer base is global and diverse, ranging from small buyers to large accounts with orders exceeding €1 million; about 60% of customers are recurring.
Product development is driven by customer demand, with a focus on quality, reliability, and continuous innovation, including the rollout of a digital app system for dosimeter readouts.
Regulatory trends in key markets (China, Canada, US) are expected to drive further adoption of quality assurance tools.
Operational structure, risk management, and capital allocation
Maintains a lean, cost-efficient structure with minimal fixed office space, prioritizing R&D and growth over overhead.
Employee retention is managed through individualized incentives, and hiring is planned across R&D, finance, sales, and marketing to support rapid growth.
Receivables risk is managed through EKN and strong customer relationships; days sales outstanding have improved but remain a focus for further reduction.
Revenue by region can fluctuate significantly due to the timing and location of large orders, with ongoing efforts to improve reporting transparency.
Capital allocation priorities include hiring, potential acquisitions, and possibly returning capital to shareholders.
Latest events from Intellego Technologies
- Massive fraud led to SEK 774m in reversed revenues; Daro drives growth amid legal and liquidity risks.INT
Q4 202520 Feb 2026 - SEK 640 million in 2025 revenue was fabricated with manipulated orders and no deliveries.INT
Investor update2 Feb 2026 - Q3 sales up 295% and EBIT margin at 58%, with strong global disinfection demand.INT
Q3 202510 Nov 2025 - Q2 2025 saw record sales and profit, with 2025 targets raised amid accelerating global growth.INT
Q2 202527 Aug 2025 - Q3 revenue up 71% year-over-year; major projects and partnerships to drive future growth.INT
Q3 202413 Jun 2025 - Record sales, profit, and cash flow in H1 2024, with strong outlook and ongoing expansion.INT
Q2 202413 Jun 2025 - Record Q1 growth and raised 2025 targets highlight Intellego's accelerating momentum.INT
Q1 20256 Jun 2025 - Strong 2024 growth, robust liquidity, and major partnerships position Intellego for 2025 expansion.INT
Q4 20245 Jun 2025